MRI-based response patterns during neoadjuvant chemotherapy can predict pathological (complete) response in patients with breast cancer

被引:54
作者
Goorts, Briete X. Z. [1 ,2 ,3 ]
Dreuning, Kelly M. A. [2 ]
Houwers, Janneke B. [3 ]
Kooreman, Loes F. S. [1 ,4 ]
Boerma, Evert-Jan G. [5 ]
Mann, Ritse M. [6 ]
Lobbes, Marc B. I. [1 ,3 ]
Smidt, Marjolein L. [1 ,2 ]
机构
[1] Maastricht Univ, Med Ctr, GROW Sch Oncol & Dev Biol, Maastricht, Netherlands
[2] Maastricht Univ, Med Ctr, Dept Surg, Maastricht, Netherlands
[3] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[4] Maastricht Univ, Med Ctr, Dept Pathol, Maastricht, Netherlands
[5] Zuyderland Med Ctr, Dept Surg, Sittard Geleen, Netherlands
[6] Radboud Univ Nijmegen, Med Ctr, Dept Radiol & Nucl Med, Nijmegen, Netherlands
来源
BREAST CANCER RESEARCH | 2018年 / 20卷
关键词
Breast Cancer; Neoadjuvant chemotherapy; Magnetic resonance imaging; RECOMMENDATIONS; THERAPY; UPDATE; TRIAL;
D O I
10.1186/s13058-018-0950-x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The main purpose was to investigate the correlation between magnetic resonance imaging (MRI)-based response patterns halfway through neoadjuvant chemotherapy and immunotherapy (NAC) and pathological tumor response in patients with breast cancer. Secondary purposes were to compare the predictive value of MRI-based response patterns measured halfway through NAC and after NAC and to measure interobserver variability.& para;& para;Methods: All consecutive patients treated with NAC for primary invasive breast cancer from 2012 to 2015 and who underwent breast MRI before, halfway through (and after) NAC were included. All breast tumors were reassessed on MRI by two experienced breast radiologists and classified into six patterns: type 0 (complete radiologic response); type 1 (concentric shrinkage); type 2 (crumbling); type 3 (diffuse enhancement); type 4 (stable disease); type 5 (progressive disease). Percentages of tumors showing pathological complete response (pCR), > 50% tumor reduction and > 50% tumor diameter reduction per MRI-based response pattern were calculated. Correlation between MRI-based response patterns and pathological tumor reduction was studied with Pearson's correlation coefficient, and interobserver agreement was tested with Cohen's Kappa.& para;& para;Results: Patients (n = 76; mean age 53, range 29-72 years) with 80 tumors (4 bilateral) were included. There was significant correlation between these MRI-based response patterns halfway through NAC and tumor reduction on pathology assessment (reader 1 r = 0.33; p = 0.003 and reader 2 r = 0.45; p < 0.001). Type-0, type-1 or type-2 patterns halfway through NAC showed highest tumor reduction rates on pathology assessment, with > 50% tumor reduction in 90%, 78% and 65% of cases, respectively. In 83% of tumors with type 0 halfway through NAC, pathology assessment showed pCR. There was no significant correlation between MRI-based response patterns after NAC and tumor reduction rates on pathology assessment (reader 1 r = - 0.17; p = 0.145 and reader 2 r = - 0.17; p = 0.146). In 41% of tumors with type 0 after NAC, pathology assessment showed pCR.& para;& para;Conclusion: MRI-based response patterns halfway through NAC can predict pathologic response more accurately than MRI-based response patterns after NAC. Complete radiological response halfway NAC is associated with 83% pCR, while complete radiological response after NAC seems to be correct in only 41% of cases.
引用
收藏
页数:10
相关论文
共 16 条
[1]   Magnetic resonance imaging tumor regression shrinkage patterns after neoadjuvant chemotherapy in patients with locally advanced breast cancer: Correlation with tumor biological subtypes and pathological response after therapy [J].
Ballesio, Laura ;
Gigli, Silvia ;
Di Pastena, Francesca ;
Giraldi, Guglielmo ;
Manganaro, Lucia ;
Anastasi, Emanuela ;
Catalano, Carlo .
TUMOR BIOLOGY, 2017, 39 (03)
[2]   Impact of Factors Affecting the Residual Tumor Size Diagnosed by MRI Following Neoadjuvant Chemotherapy in Comparison to Pathology [J].
Chen, Jeon-Hor ;
Bahri, Shadfar ;
Mehta, Rita S. ;
Carpenter, Philip M. ;
Mclaren, Christine E. ;
Chen, Wen-Pin ;
Fwu, Peter T. ;
Hsiang, David J. B. ;
Lane, Karen T. ;
Butler, John A. ;
Su, Min-Ying .
JOURNAL OF SURGICAL ONCOLOGY, 2014, 109 (02) :158-167
[3]   Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancer [J].
Golden, Daniel I. ;
Lipson, Jafi A. ;
Telli, Melinda L. ;
Ford, James M. ;
Rubin, Daniel L. .
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2013, 20 (06) :1059-1066
[4]  
Gonzalez-Angulo AM, 2007, ADV EXP MED BIOL, V608, P1
[5]   Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients [J].
Goorts, Briete ;
van Nijnatten, Thiemo J. A. ;
de Munck, Linda ;
Moossdorff, Martine ;
Heuts, Esther M. ;
de Boer, Maaike ;
Lobbes, Marc B. I. ;
Smidt, Marjolein L. .
BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (01) :83-91
[6]   Locally Advanced Breast Cancer: MR Imaging for Prediction of Response to Neoadjuvant Chemotherapy-Results from ACRIN 6657/I-SPY TRIAL [J].
Hylton, Nola M. ;
Blume, Jeffrey D. ;
Bernreuter, Wanda K. ;
Pisano, Etta D. ;
Rosen, Mark A. ;
Morris, Elizabeth A. ;
Weatherall, Paul T. ;
Lehman, Constance D. ;
Newstead, Gillian M. ;
Polin, Sandra ;
Marques, Helga S. ;
Esserman, Laura J. ;
Schnall, Mitchell D. .
RADIOLOGY, 2012, 263 (03) :663-672
[7]   Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: An update [J].
Kaufmann, M ;
Hortobagyi, GN ;
Goldhirsch, A ;
Scholl, S ;
Makris, A ;
Valagussa, P ;
Blohmer, JU ;
Eiermann, W ;
Jackesz, R ;
Jonat, W ;
Lebeau, A ;
Loibl, S ;
Miller, W ;
Seeber, S ;
Semiglazov, V ;
Smith, R ;
Souchon, R ;
Stearns, V ;
Untch, M ;
von Minckwitz, G .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (12) :1940-1949
[8]   Magnetic Resonance Imaging Patterns of Tumor Regression After Neoadjuvant Chemotherapy in Breast Cancer Patients: Correlation With Pathological Response Grading System Based on Tumor Cellularity [J].
Kim, Tae Hee ;
Kang, Doo Kyoung ;
Yim, Hyunee ;
Jung, Yong Sik ;
Kim, Ku Sang ;
Kang, Seok Yun .
JOURNAL OF COMPUTER ASSISTED TOMOGRAPHY, 2012, 36 (02) :200-206
[9]   MEASUREMENT OF OBSERVER AGREEMENT FOR CATEGORICAL DATA [J].
LANDIS, JR ;
KOCH, GG .
BIOMETRICS, 1977, 33 (01) :159-174
[10]   Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer [J].
Liedtke, Cornelia ;
Mazouni, Chafika ;
Hess, Kenneth R. ;
Andre, Fabrice ;
Tordai, Attila ;
Mejia, Jaime A. ;
Symmans, W. Fraser ;
Gonzalez-Angulo, Ana M. ;
Hennessy, Bryan ;
Green, Marjorie ;
Cristofanilli, Massimo ;
Hortobagyi, Gabriel N. ;
Pusztai, Lajos .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (08) :1275-1281